Sep 30, 2021 03:29:01 EDTNEJM EvidenceCarmel Hawley

Summary of Interests

I do not have any interests to disclose at this time.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: EVIDENCE-21-00021

Sep 22, 2021 23:23:22 EDTNEJM EvidenceMargaret Allman-Farinelli

Summary of Interests

Company or Organization

Entity Type Interest Held By

Australian Research Council Grant / Contract Self

Cancer Council NSW Grant / Contract Self

National Health and Medical Research Council Grant / Contract Other - Lead investigators managed funds; Lisa Bero and Gopala Rangan

NSW Health Grant / Contract Other - School of Public Health holds the funds

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: EVIDENCE-21-00021

Recipient Name: The University of Sydney Recipient Type: InstitutionGrant / Contract Description: Competitive funding for a research project Grant / Contract Purpose: ResearchAdditional Information: I was the lead investigator

Recipient Name: The University of Sydney Recipient Type: InstitutionGrant / Contract Description: Competitive research funding Grant / Contract Purpose: ResearchAdditional Information: I was lead investigator

Recipient Name: The University of Sydney Recipient Type: InstitutionGrant / Contract Description: Competitive grant process. Two awards. Grant / Contract Purpose: ResearchAdditional Information:

Recipient Name: The University of Sydney Recipient Type: InstitutionGrant / Contract Description: Competitive contract to the School of Public Health at the university Grant / Contract Purpose: ResearchAdditional Information:

Sep 22, 2021 18:23:43 EDTNEJM EvidenceSunil Badve

Summary of Interests

I do not have any interests to disclose at this time.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: EVIDENCE-21-00021

Sep 23, 2021 04:38:23 EDTNEJM EvidenceNeil Boudville

Summary of Interests

Company or Organization

Entity Type Interest Held By

Amgen Travel Self

Baxter Healthcare Corporation Grant / Contract Self

Baxter Healthcare Corporation Consultant Self

Roche Products Limited Grant / Contract Self

Roche Products Limited Travel Self

Vifor Pharma Consultant Self

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: EVIDENCE-21-00021

Location(s): ASN Kidney Week 2016 Purpose: EducationAdditional Information:

Recipient Name: Neil Boudville Recipient Type: IndividualGrant / Contract Description: TEACH PD pilot study grant Grant / Contract Purpose: ResearchAdditional Information:

Category: Consultant Description: Global Peritoneal Dialysis CommitteeAdditional Information:

Recipient Name: Neil Boudville Recipient Type: IndividualGrant / Contract Description: Unrestricted educational grant Grant / Contract Purpose: ResearchAdditional Information:

Location(s): ASN Kidney Week 2017 Purpose: EducationalAdditional Information:

Category: Consultant Description: Advisory Board memberAdditional Information:

Sep 22, 2021 20:53:28 EDTNEJM EvidenceJessie Chan

Summary of Interests

I do not have any interests to disclose at this time.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: EVIDENCE-21-00021

Sep 23, 2021 00:35:58 EDTNEJM EvidenceHelen Coolican

Summary of Interests

I do not have any interests to disclose at this time.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: EVIDENCE-21-00021

Oct 06, 2021 05:20:53 EDTNEJM EvidenceSusan Coulshed

Summary of Interests

I do not have any interests to disclose at this time.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: EVIDENCE-21-00021

Sep 22, 2021 16:28:39 EDTNEJM EvidenceMarie Edwards

Summary of Interests

I do not have any interests to disclose at this time.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: EVIDENCE-21-00021

Sep 29, 2021 11:35:58 EDTNEJM EvidenceBradley Erickson

Summary of Interests

Company or Organization

Entity Type Interest Held By

FlowSIGMA,Inc. Fiduciary Officer Self

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: EVIDENCE-21-00021

Official Title: Chief Medical Officer Position Description:Additional Information:

Sep 22, 2021 22:07:46 EDTNEJM EvidenceMANGALEE FERNANDO

Summary of Interests

I do not have any interests to disclose at this time.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: EVIDENCE-21-00021

Sep 28, 2021 20:03:47 EDTNEJM EvidenceSheryl Foster

Summary of Interests

I do not have any interests to disclose at this time.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: EVIDENCE-21-00021

Sep 28, 2021 21:25:02 EDTNEJM EvidenceAdriana Gregory

Summary of Interests

I do not have any interests to disclose at this time.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: EVIDENCE-21-00021

Sep 22, 2021 18:32:01 EDTNEJM EvidenceImad Haloob

Summary of Interests

I do not have any interests to disclose at this time.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: EVIDENCE-21-00021

ICMJE Form for Disclosure of Potential Conflicts of Interest

1Harris

The purpose of this form is to provide readers of your manuscript with information about your other interests that could

influence how they receive and understand your work. The form is designed to be completed electronically and stored

electronically. It contains programming that allows appropriate data display. Each author should submit a separate

form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Instructions

1.

2.

3.

4.

5.

Other: Anything not covered under the previous three boxes Pending: The patent has been filed but not issued Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

Entity: government agency, foundation, commercial sponsor, academic institution, etc. Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting , lectures, speakers bureaus, expert testimony, employment, or other affiliations Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

ICMJE Form for Disclosure of Potential Conflicts of Interest

2Harris

Identifying Information Section 1.

1. Given Name (First Name)David

2. Surname (Last Name) Harris

4. Are you the corresponding author? Yes No✔

3. Date15-October-2021

Corresponding Author’s Name

Gopal Rangan

5. Manuscript TitlePrescribed Water Intake in Autosomal Dominant Polycystic Kidney Disease

6. Manuscript Identifying Number (if you know it)EVIDENCE-21-00021

The Work Under Consideration for PublicationSection 2.

Did you or your institution at any time receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?Are there any relevant conflicts of interest? Yes No✔

Relevant financial activities outside the submitted work.Section 3.

Are there any relevant conflicts of interest? Yes No✔

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were present during the 36 months prior to publication.

Intellectual Property -- Patents & CopyrightsSection 4.

Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes No✔

ICMJE Form for Disclosure of Potential Conflicts of Interest

3Harris

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

Yes, the following relationships/conditions/circumstances are present (explain below):

No other relationships/conditions/circumstances that present a potential conflict of interest ✔

Relationships not covered aboveSection 5.

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Disclosure StatementSection 6.

Dr. Harris has nothing to disclose.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Sep 23, 2021 01:07:19 EDTNEJM EvidenceJane Holt

Summary of Interests

I do not have any interests to disclose at this time.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: EVIDENCE-21-00021

Sep 22, 2021 18:20:27 EDTNEJM EvidenceKirsten Howard

Summary of Interests

I do not have any interests to disclose at this time.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: EVIDENCE-21-00021

Sep 22, 2021 18:22:04 EDTNEJM EvidenceMartin Howell

Summary of Interests

I do not have any interests to disclose at this time.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: EVIDENCE-21-00021

Sep 22, 2021 17:49:50 EDTNEJM EvidenceDavid Johnson

Summary of Interests

Company or Organization

Entity Type Interest Held By

Amgen Travel Self

AstraZeneca Consultant Self

AWAK Consultant Self

BAXTER HEALTHCARE Consultant Self

Baxter Healthcare Corporation Consultant Self

Bayer Consultant Self

Boehringer Ingelheim Other Self

Ono Consultant Self

Vifor Fresenius Medical Care Renal Pharma Ltd. Consultant Self

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: EVIDENCE-21-00021

Location(s): USA Purpose: Attend American Society of Nephrology Kidney WeekAdditional Information:

Category: Consultant Description: Advised on SGLT-2 inhibitors and prolylhydroxylase inhibitorsAdditional Information:

Category: Consultant Description: Provide advice on dialysis deviceAdditional Information:

Category: Consultant Description: Provide education at Peritoneal Dialysis AcademyAdditional Information:

Category: Consultant Description: Advised on remote peritoneal dialysis monitoringAdditional Information:

Category: Consultant Description: Consultant Advisory BoardAdditional Information:

Category: Other Description: Speaker's honorariumAdditional Information:

Category: Consultant Description: Invited lecture at Asia-Pacific Chapter Meeting of ISPDAdditional Information:

Category: Consultant Description: Invited speaking tour across CanadaAdditional Information:

Oct 13, 2021 09:36:25 EDTNEJM EvidenceTimothy Kline

Summary of Interests

I do not have any interests to disclose at this time.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: EVIDENCE-21-00021

Sep 22, 2021 15:31:21 EDTNEJM EvidenceSubramanian Kumar

Summary of Interests

Company or Organization

Entity Type Interest Held By

Amgen Travel Self

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: EVIDENCE-21-00021

Location(s): USA Purpose: Travel for conferencesAdditional Information:

Sep 22, 2021 10:25:31 EDTNEJM EvidenceVincent Lee

Summary of Interests

Company or Organization

Entity Type Interest Held By

Otsuka Pharmaceutical Other Self

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: EVIDENCE-21-00021

Category: Other Description: Preceptorship to the Mayo clinicAdditional Information: 2 day preceptorship at the Mayo Clinic, Minnesota on ADPKD.

Sep 24, 2021 00:11:37 EDTNEJM EvidenceMaureen Lonergan

Summary of Interests

I do not have any interests to disclose at this time.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: EVIDENCE-21-00021

Sep 26, 2021 22:43:37 EDTNEJM EvidenceSandra LOUW

Summary of Interests

Company or Organization

Entity Type Interest Held By

McCloud Consulting Group Employment Self

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: EVIDENCE-21-00021

Title: Statistician Position Description: Statistical analysis and designAdditional Information:

Oct 05, 2021 22:43:58 EDTNEJM EvidenceJun Mai

Summary of Interests

I do not have any interests to disclose at this time.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: EVIDENCE-21-00021

Sep 23, 2021 02:58:41 EDTNEJM EvidencePhilip McCloud

Summary of Interests

Company or Organization

Entity Type Interest Held By

McCloud Consulting Group Other Business Ownership Self

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: EVIDENCE-21-00021

Form of Business Description: Statistical and Data Management Consulting Services Additional Information:

Sep 22, 2021 18:44:43 EDTNEJM EvidenceAlexandra Munt

Summary of Interests

I do not have any interests to disclose at this time.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: EVIDENCE-21-00021

Sep 22, 2021 21:22:14 EDTNEJM EvidenceElaine Pascoe

Summary of Interests

I do not have any interests to disclose at this time.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: EVIDENCE-21-00021

Sep 28, 2021 19:43:37 EDTNEJM EvidenceAnthony Peduto

Summary of Interests

I do not have any interests to disclose at this time.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: EVIDENCE-21-00021

Sep 22, 2021 19:16:39 EDTNEJM EvidenceAnna Rangan

Summary of Interests

I do not have any interests to disclose at this time.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: EVIDENCE-21-00021

Sep 22, 2021 10:22:34 EDTNEJM EvidenceGopala Rangan

Summary of Interests

Company or Organization

Entity Type Interest Held By

Danone Grant / Contract Self

National Health and Medical Research Council Grant / Contract Self

Otsuka Pharmaceutical Grant / Contract Self

PKD Australia Grant / Contract Self

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: EVIDENCE-21-00021

Recipient Name: Gopala Rangan Recipient Type: InstitutionGrant / Contract Description: The grant was paid to the Westmead Hospital, and was used to conductthe current clinical trial.

Grant / Contract Purpose: ResearchAdditional Information:

Recipient Name: Gopala Rangan Recipient Type: InstitutionGrant / Contract Description: The funds were paid to the University of Sydney to conduct the currentclinical trial.

Grant / Contract Purpose: ResearchAdditional Information:

Recipient Name: Gopala Rangan Recipient Type: InstitutionGrant / Contract Description: To conduct research and a research meeting related to polycystic kidneydisease

Grant / Contract Purpose: ResearchAdditional Information:

Recipient Name: Gopala Rangan Recipient Type: InstitutionGrant / Contract Description: The funds were paid to the Institute and used to conduct the currentclinical trial.

Grant / Contract Purpose: ResearchAdditional Information:

Sep 29, 2021 18:56:10 EDTNEJM Evidencesimon roger

Summary of Interests

I do not have any interests to disclose at this time.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: EVIDENCE-21-00021

Oct 02, 2021 22:55:13 EDTNEJM EvidenceSayanthooran Saravanabavan

Summary of Interests

I do not have any interests to disclose at this time.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: EVIDENCE-21-00021

Oct 07, 2021 18:27:33 EDTNEJM EvidenceJulie Sherfan

Summary of Interests

Company or Organization

Entity Type Interest Held By

Thermo Fisher Scientific Grant / Contract Self

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: EVIDENCE-21-00021

Recipient Name: NSW Health Pathology Recipient Type: InstitutionGrant / Contract Description: Thermo Fisher Scientific provided discounted Copeptin reagent kits forPREVENT study

Grant / Contract Purpose: ResearchAdditional Information: 50% discount of Copeptin reagent kits.

Sep 22, 2021 22:57:57 EDTNEJM EvidenceKamal Sud

Summary of Interests

I do not have any interests to disclose at this time.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: EVIDENCE-21-00021

Oct 01, 2021 12:34:54 EDTNEJM Evidencevicente torres

Summary of Interests

Company or Organization

Entity Type Interest Held By

Blueprint Medicines Corporation Grant / Contract Other - Mayo Clinic

Mironid Grant / Contract Other - Mayo Clinic

Otsuka America Pharmaceutical, Inc. Other Other - Mayo Clinic

Palladio Biosciences Other Other - Mayo Clinic

Palladio Biosciences Other Other - Mayo Clinic

Reata Pharmaceuticals Other Other - Mayo Clinic

Regulus Therapeutics Other Other - Mayo Clinic

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: EVIDENCE-21-00021

Recipient Name: Mayo Clinic Recipient Type: InstitutionGrant / Contract Description: Effect of a PKA inhibitor in PKD Grant / Contract Purpose: ResearchAdditional Information:

Recipient Name: Mayo Clinic Recipient Type: InstitutionGrant / Contract Description: Effect of PDE4 activator in PKD Grant / Contract Purpose: ResearchAdditional Information:

Category: Other Description: Scientific Advisory BoardAdditional Information:

Category: Other Description: Clinical trialAdditional Information: Chair, Steering Committee

Category: Other Description: Clinical trialAdditional Information:

Category: Other Description: Clinical trialAdditional Information:

Category: Other Description: Clinical trialAdditional Information:

Sep 23, 2021 07:26:04 EDTNEJM EvidenceEswari Vilayur

Summary of Interests

I do not have any interests to disclose at this time.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: EVIDENCE-21-00021

Sep 24, 2021 02:29:59 EDTNEJM EvidenceAnnette Wong

Summary of Interests

Company or Organization

Entity Type Interest Held By

Danone Travel Self

National Health and Medical Research Council Grant / Contract Self

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: EVIDENCE-21-00021

Location(s): Evian, France Purpose: Hydration 4 Health Annual ConferenceAdditional Information:

Recipient Name: Gopala Rangan Recipient Type: IndividualGrant / Contract Description: Grant funding for the PREVENT-ADPKD Clinical trial. Grant / Contract Purpose: ResearchAdditional Information: My salary is supported through this grant. I am a listed chief investigator ofthis grant.

Sep 23, 2021 21:26:27 EDTNEJM EvidenceJennifer Zhang

Summary of Interests

I do not have any interests to disclose at this time.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: EVIDENCE-21-00021